CO2019009432A2 - Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. - Google Patents
Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.Info
- Publication number
- CO2019009432A2 CO2019009432A2 CONC2019/0009432A CO2019009432A CO2019009432A2 CO 2019009432 A2 CO2019009432 A2 CO 2019009432A2 CO 2019009432 A CO2019009432 A CO 2019009432A CO 2019009432 A2 CO2019009432 A2 CO 2019009432A2
- Authority
- CO
- Colombia
- Prior art keywords
- binding
- fap
- bispecific antigen
- molecules capable
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La invención se refiere a nuevas moléculas de unión a antígeno biespecíficas, que comprenden (a) al menos un dominio de unión a antígeno capaz de unirse específicamente a CD40 y (b) al menos un dominio de unión a antígeno capaz de unirse específicamente a un antígeno de célula diana, en particular, proteína de activación de fibroblastos (FAP) y a métodos para producir estas moléculas y a métodos para usar las mismas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164725 | 2017-04-04 | ||
EP18158751 | 2018-02-27 | ||
PCT/EP2018/058384 WO2018185045A1 (en) | 2017-04-04 | 2018-04-03 | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019009432A2 true CO2019009432A2 (es) | 2019-09-18 |
Family
ID=61913152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0009432A CO2019009432A2 (es) | 2017-04-04 | 2019-08-29 | Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. |
Country Status (20)
Country | Link |
---|---|
US (2) | US20180340030A1 (es) |
EP (1) | EP3606956A1 (es) |
JP (2) | JP6997209B2 (es) |
KR (1) | KR102364599B1 (es) |
CN (1) | CN110402255B (es) |
AU (1) | AU2018247796A1 (es) |
BR (1) | BR112019017753A2 (es) |
CA (1) | CA3053358A1 (es) |
CL (1) | CL2019002542A1 (es) |
CO (1) | CO2019009432A2 (es) |
CR (1) | CR20190427A (es) |
IL (1) | IL269396A (es) |
MA (1) | MA49039A (es) |
MX (1) | MX2019011907A (es) |
PE (1) | PE20200006A1 (es) |
PH (1) | PH12019502294A1 (es) |
RU (1) | RU2766234C2 (es) |
SG (1) | SG11201908787WA (es) |
TW (1) | TWI704158B (es) |
WO (1) | WO2018185045A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3559034B1 (en) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
BR112019013189A2 (pt) | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
CN110573528B (zh) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
EP3703821A2 (en) * | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Bispecific 2+1 contorsbodies |
CN111819198A (zh) | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白;TRAAFFIAA) |
US20200048350A1 (en) * | 2018-07-24 | 2020-02-13 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
JP7221379B2 (ja) | 2018-10-01 | 2023-02-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗fapクローン212を含む二重特異性抗原結合分子 |
MY198034A (en) | 2018-12-21 | 2023-07-27 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
JPWO2020230899A1 (es) | 2019-05-15 | 2020-11-19 | ||
JPWO2020230901A1 (es) * | 2019-05-15 | 2020-11-19 | ||
UY38995A (es) | 2019-12-20 | 2021-06-30 | Amgen Inc | Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
WO2021229067A1 (en) * | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Multispecific proteins |
EP4244254A1 (en) | 2020-11-16 | 2023-09-20 | F. Hoffmann-La Roche AG | Combination therapy with fap-targeted cd40 agonists |
BR112023018117A2 (pt) | 2021-03-09 | 2023-10-31 | Hoffmann La Roche | Imunoconjugados |
WO2022243261A1 (en) * | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
CN117616049A (zh) * | 2021-08-24 | 2024-02-27 | 江苏恒瑞医药股份有限公司 | Fap/cd40结合分子及其医药用途 |
WO2023046037A1 (zh) * | 2021-09-24 | 2023-03-30 | 正大天晴药业集团股份有限公司 | 抗cd40抗体及其用途 |
CN116410326A (zh) * | 2021-12-30 | 2023-07-11 | 三优生物医药(上海)有限公司 | 抗cd40×cldn18.2双特异性抗体及其用途 |
CN114480413B (zh) * | 2022-01-14 | 2022-11-04 | 北京贝来生物科技有限公司 | 一种活化肿瘤免疫应答的基因修饰干细胞制备方法 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
AU2004253835B2 (en) | 2003-07-04 | 2009-01-29 | Affibody Ab | Polypeptides having binding affinity for HER2 |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8303955B2 (en) * | 2005-05-26 | 2012-11-06 | Seattle Genetics, Inc. | Humanized anti-CD40 antibodies and their methods of use |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
JP5730576B2 (ja) * | 2007-11-07 | 2015-06-10 | ジェネンテック, インコーポレイテッド | 抗cd40抗体による治療に対するb細胞リンパ腫の応答性を評価するための方法及び組成物 |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2012002006A1 (ja) | 2010-06-29 | 2012-01-05 | コニカミノルタエムジー株式会社 | 超音波診断装置及びプログラム |
SG187746A1 (en) * | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
PE20140303A1 (es) * | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
CN103748114B (zh) * | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T细胞活化性双特异性抗原结合分子 |
ES2774160T3 (es) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
SG10201800535XA (en) * | 2012-08-07 | 2018-02-27 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
US10131710B2 (en) * | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
JP6618463B2 (ja) * | 2013-05-07 | 2019-12-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 三量体型抗原結合分子 |
GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
WO2015132598A1 (en) * | 2014-03-05 | 2015-09-11 | Ucl Business Plc | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
RU2017108173A (ru) * | 2014-08-14 | 2018-09-17 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 |
WO2016030350A1 (en) | 2014-08-29 | 2016-03-03 | F. Hoffmann-La Roche Ag | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
CN107074933B (zh) | 2014-10-24 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 基于vh-vl域间角的抗体人源化 |
BR112017010324A2 (pt) * | 2014-11-20 | 2018-05-15 | F. Hoffmann-La Roche Ag | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula |
WO2017025698A1 (en) * | 2015-08-11 | 2017-02-16 | Queen Mary University Of London | Bispecific, cleavable antibodies |
JP7221379B2 (ja) * | 2018-10-01 | 2023-02-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗fapクローン212を含む二重特異性抗原結合分子 |
-
2018
- 2018-04-03 BR BR112019017753A patent/BR112019017753A2/pt active Search and Examination
- 2018-04-03 MA MA049039A patent/MA49039A/fr unknown
- 2018-04-03 JP JP2019554378A patent/JP6997209B2/ja active Active
- 2018-04-03 TW TW107111767A patent/TWI704158B/zh active
- 2018-04-03 RU RU2019134352A patent/RU2766234C2/ru active
- 2018-04-03 PE PE2019001678A patent/PE20200006A1/es unknown
- 2018-04-03 US US15/943,821 patent/US20180340030A1/en not_active Abandoned
- 2018-04-03 MX MX2019011907A patent/MX2019011907A/es unknown
- 2018-04-03 EP EP18716574.1A patent/EP3606956A1/en active Pending
- 2018-04-03 SG SG11201908787W patent/SG11201908787WA/en unknown
- 2018-04-03 WO PCT/EP2018/058384 patent/WO2018185045A1/en unknown
- 2018-04-03 KR KR1020197032424A patent/KR102364599B1/ko active IP Right Grant
- 2018-04-03 AU AU2018247796A patent/AU2018247796A1/en active Pending
- 2018-04-03 CR CR20190427A patent/CR20190427A/es unknown
- 2018-04-03 CN CN201880015543.7A patent/CN110402255B/zh active Active
- 2018-04-03 CA CA3053358A patent/CA3053358A1/en active Pending
-
2019
- 2019-08-29 CO CONC2019/0009432A patent/CO2019009432A2/es unknown
- 2019-09-04 CL CL2019002542A patent/CL2019002542A1/es unknown
- 2019-09-16 IL IL26939619A patent/IL269396A/en unknown
- 2019-10-04 PH PH12019502294A patent/PH12019502294A1/en unknown
-
2021
- 2021-02-18 US US17/179,223 patent/US20210188992A1/en active Pending
- 2021-10-07 JP JP2021165225A patent/JP7288943B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018185045A1 (en) | 2018-10-11 |
EP3606956A1 (en) | 2020-02-12 |
SG11201908787WA (en) | 2019-10-30 |
KR102364599B1 (ko) | 2022-02-21 |
JP2022017275A (ja) | 2022-01-25 |
TW201841939A (zh) | 2018-12-01 |
JP7288943B2 (ja) | 2023-06-08 |
RU2766234C2 (ru) | 2022-02-10 |
PE20200006A1 (es) | 2020-01-06 |
CL2019002542A1 (es) | 2020-01-31 |
AU2018247796A1 (en) | 2019-08-29 |
CR20190427A (es) | 2019-11-01 |
JP6997209B2 (ja) | 2022-02-04 |
BR112019017753A2 (pt) | 2020-04-07 |
US20210188992A1 (en) | 2021-06-24 |
MA49039A (fr) | 2020-02-12 |
TWI704158B (zh) | 2020-09-11 |
CN110402255A (zh) | 2019-11-01 |
CA3053358A1 (en) | 2018-10-11 |
MX2019011907A (es) | 2020-01-09 |
RU2019134352A3 (es) | 2021-07-21 |
PH12019502294A1 (en) | 2020-07-06 |
JP2020515276A (ja) | 2020-05-28 |
IL269396A (en) | 2019-11-28 |
US20180340030A1 (en) | 2018-11-29 |
RU2019134352A (ru) | 2021-05-05 |
KR20190137125A (ko) | 2019-12-10 |
CN110402255B (zh) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019009432A2 (es) | Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. | |
ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
CO2018000710A2 (es) | Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador | |
CL2021000751A1 (es) | Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap | |
CO2019007046A2 (es) | Moléculas de unión a antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb | |
CO2017013710A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t. | |
CR20170203A (es) | Moleculas de unión a antígeno biespecíficas activadoras de células t | |
CO2020009234A2 (es) | Anticuerpos anti-pd-1 y métodos de tratamiento | |
MX2020004571A (es) | Contorsbodies 2+1 biespecificos. | |
DOP2020000245A (es) | Anticuerpos il-11 | |
CR20170032A (es) | Moleculas biespecíficas de unión a antígeno activadoras de células t | |
AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
DOP2020000236A (es) | Anticuerpos il-1 1ra | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
BR112019012342A2 (pt) | anticorpos il-11 | |
MX2020003857A (es) | Anticuerpos anti-tau y uso de los mismos. | |
CR20190417A (es) | Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas | |
CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
CL2022002647A1 (es) | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap | |
BR112018014355A2 (pt) | processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii | |
CR20190193A (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
ECSP16076535A (es) | Proteínas de fusión uti | |
EA201892096A1 (ru) | Нейтрализующие моноклональные антитела к il-25 и их применение |